NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.

The NSB product portfolio includes several therapeutic peptides that are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II).

EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II and is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve.

KEY PEOPLE

  • Dr Anton Uvarov, Executive Director

    Dr Anton Uvarov has significant experience as an equity analyst, both domestically and internationally, and is particularly interested in early-stage startups. Prior to his move to Australia, Dr Uvarov was senior associate at Citigroup Global Markets where he spent two years as a member of New York based healthcare team. In 2013, Dr Uvarov joined the boards of Actinogen Medical and Imugene. Dr Uvarov has a PhD from University of Manitoba, Canada and an MBA from University of Calgary, Canada.

    read more

  • Stephen Quantrill, Director

    Stephen Quantrill acts as chairman and director of a range of businesses, including in private equity, real estate property, oil and gas, bio-technology, advisory and engineering. He is the executive chairman of McRae Investments, the diversified investment holding company founded by Harold Clough in 1965, and is executive chairman of The Indo-Pacific Group, of Strategius and of Fang Australia, which is the Australian arm of NYSElisted SouFun Holdings, owner of China’s largest real estate property portal Fang.com. He is also managing director of Q-Corporate Advisory, director of Alzhyme Pty Ltd, an alternate director of Twinza Oil Limited, chairman of Pedco Engineering and director of Q-Boss Process Solutions. He holds a BSc (Civil Engineering), Bachelor of Commerce, and an MBA – all with first class honours, and draws on global business experiences across Australia, Asia, the USA, Southern Africa and Europe. He is a Fellow of FINSIA, Graduate member of the Australian Institute of Company Directors, a member of Engineers Australia and member of the Turnaround Management Association of Australia.

    read more

  • Paul Rennie, Director

    Paul Rennie has sales, marketing, business development, operational and IP commercialisation experience in the biopharmaceutical sector. His experience includes working for Boehringer Mannheim (now Roche Diagnostics), Merck KGGA as national sales and marketing manager, and as director of business development at Soltec (FH Faulding). Mr Rennie also led the commercialisation of Recaldent, a novel biopharmaceutical arising from research at the dental school, University of Melbourne. He has worked in a number of positions with Mesoblast, and was the inaugural chief operating officer and executive vice president of new product development for the adult stem cell company

    read more

RELATED STOCKHEAD STORIES